Literature DB >> 24456888

Secondary amyloidosis in an alkaptonuric aortic valve.

Lia Millucci1, Lorenzo Ghezzi1, Daniela Braconi1, Marcella Laschi1, Michela Geminiani1, Loredana Amato1, Maurizio Orlandini1, Chiara Benvenuti2, Giulia Bernardini1, Annalisa Santucci3.   

Abstract

Entities:  

Keywords:  Amyloidosis; Aortic valve; Calcification; Ochronosis; Stenosis

Mesh:

Year:  2014        PMID: 24456888      PMCID: PMC3991337          DOI: 10.1016/j.ijcard.2013.12.117

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


× No keyword cloud information.
Alkaptonuria (AKU) is an ultra-rare disease developed from the lack of homogentisate 1,2-dioxygenase activity, causing an accumulation of homogentisic acid (HGA) in pigmented deposits (ochronosis) in connective tissues, especially in the joints and heart. AKU is mostly asymptomatic in early life, with arthropathy and cardiovascular symptoms appearing in later decades of life. Cardiovascular involvement has been described in as many as 40% of AKU patients (mean and median age of detection being 54 and 52 years, respectively) [1]. Alkaptonuric ochronosis can be treated symptomatically during the early stages, whereas for end stages total joint and heart valve replacements may be required [1-3], but no specific cure exists at the moment, although a phase II clinical trial with nitisinone is in progress. Thanks to the use of our in vitro, cell and tissue AKU models [4-10], we recently provided experimental evidence that AKU is a secondary serum amyloid A (SAA)-based amyloidosis [8]. A co-localization of ochronotic pigment and SAA-amyloid was also reported [8]. In the present work, using Congo Red (CR) birefringence and immunofluorescence, we report for the first time the presence of SAA-amyloidosis in the stenotic aortic valve of an AKU patient. Light microscopy revealed a co-localization of ochronotic pigment and SAA-amyloid, tissue calcification, lipid oxidation, inflammation, and tissue degeneration. Alkaptonuric specimen was obtained from a patient (Table 1) who underwent biologic aortic valve replacement. AKU patient had been previously diagnosed for secondary amyloidosis as SAA-amyloid had been detected in her cartilage and synovia [8]. Echocardiogram revealed severe aortic stenosis with an aortic transvalvular mean gradient of 53 mm Hg, a peak transvalvular gradient of 89, a peak of systolic velocity (m/s) of 4.7 and valve area of 0.82 cm2 and an AVA indexed for body weight of 0.52 cm2. Inter-ventricular septal thickness was 12 mm. Left ventricular systolic function was preserved. In view of the severe aortic stenosis the patient underwent elective aortic valve replacement. The postoperative course was uneventful and the patient recovered well from surgery at one-year follow-up.
Table 1

Clinical history of the patient.

Sex year of birthFemale 1948
1985Meniscus break (L)
19863 lumbosciatica attacksReduction in spinal discsSpondylolisthesisAKU diagnosis
1987Low proteins diet: no resultsTiroxina with C protein
1989Meniscus break (R)
1994Achilles' tendon thickening (L)
1997DroolingHiatus herniaEsophagitis (II degree)
1998Ulna and radial head capitellum break (R)
2001Knee rotuleus tendon break (L)
2003Macroglossia
2005Thyroid removalHip prosthesis (R) with bone replacement
2006Hip prosthesis (L)
2008TachycardiaAortic valve stenosis
20102 ribs break
2011Aortic valve replacement
AKU featuresElbows and heels bursitisShoulder pain15 cm decline of heightAmyloid deposits in cartilage, synovia and aortic valve
SAA plasma level110 mg/L
SAP plasma level50 μg/L
HGA plasma level11 μg/mL
HGA urine excretion8.6 g/day
HGD MutationG270R
After surgery AKU aortic valve sections were stained with eosin/hematoxylin, CR stained for amyloid detection or used for immunofluorescence staining with anti-SAA and anti-4-hydroxy-2-nonenal (4-HNE) antibodies. At a glance, the aortic valve revealed massive deposits of ochronotic pigment with calcification in the cusps (Fig. 1A). Sclerotic change in the cusps, and shrinkage of the non-coronary cusp, impeding normal coaptation of the aortic valve, associated with diffuse ochronotic deposition, appeared to be the causative lesions of the need for aortic valve replacement. Ochronosis was associated with areas of valvular calcification. Light microscopy examinations consistently showed severe calcification involving surface endothelium (Fig. 1B). CR staining detected the presence of diffuse amyloid, mainly located in densely sclerotic and poorly vascularised scar tissue and co-localization of amyloid and ochronotic pigment was visible in close proximity to calcific deposits (Fig. 1C). Co-localization of SAA deposition with ochronotic pigmentation was detected (Fig. 1D). Major products of lipid peroxidation (LPO) were detected in AKU valve sections incubated with anti-4-HNE antibody (Fig. 1E). LPO were perfectly superimposing to pigmented areas, suggesting the association of intraleaflet ochronosis and oxidative stress (Fig. 1E). AKU valve also contained macrophages in the subendothelial layer of the fibrosa, in the vicinity of ochronotic deposits, and along the lamina elastic (Fig. 1B). An evident co-localization between oxidized lipids, inflammation and ochronosis suggested that LPO might play a role in the disease process.
Fig. 1

A) Macroscopic aspect of AKU aortic valve showing a rough surface of the leaflets and ochronotic pigmentation on the surface. A thickening of the central areas of the cusps with nodule-like structures is visible (arrow). B) Light microscopy (hematoxylin and eosin staining) examinations of AKU aortic valve with intense inflammatory cell infiltrate that includes large cells macroscopically corresponding to macrophages (arrows). Magnification 20 ×. C) Congo Red staining of AKU aortic valve amyloid deposits. Left: unpolarized light. Valve tissue was ever stained red (“congophilic”); Right: polarized light. The pigmented areas (arrows) were also birefringent, indicating overlapping of ochronosis and amyloid. Magnification 40 ×. D) SAA was present in AKU aortic valve amyloid deposits. Positive staining for SAA-amyloid was particularly intense in correspondence of ochronotic pigmentation. Magnification 20 ×. E) Immunoreactivity for 4-HNE in AKU aortic valve leaflet. The presence of 4-HNE in the AKU valve was uniformly diffused and the distribution of 4-HNE-positive area was perfectly superimposing to ochronotic pigmented areas. The presence of lipid peroxidation and ochronotic pigment was found to be strictly related to areas of lymphocytes accumulation. Magnification 20 ×.

Our present investigation confirmed the hitherto unsuspected existence of AKU-linked secondary amyloidosis, involving also the cardiac district. The present case report is therefore a new rare case of SAA amyloidosis in the heart. The striking co-localization of pigment and amyloid suggested that HGA might be involved in amyloid deposition in the heart. In conclusion, the emerging view in this AKU case is that valve calcification represents a meeting of lipid oxidation with chronic inflammation and amyloid deposition. In AKU cases, surgical replacement of aortic valves results in significant improvement. Physicians and surgeons should be aware of multiple system involvement in this disorder, as early recognition and appropriate treatment may significantly improve the quality of life in AKU patients.
  10 in total

1.  Evaluation of antioxidant drugs for the treatment of ochronotic alkaptonuria in an in vitro human cell model.

Authors:  Laura Tinti; Adriano Spreafico; Daniela Braconi; Lia Millucci; Giulia Bernardini; Federico Chellini; Giovanni Cavallo; Enrico Selvi; Mauro Galeazzi; Roberto Marcolongo; James A Gallagher; Annalisa Santucci
Journal:  J Cell Physiol       Date:  2010-10       Impact factor: 6.384

2.  Aortic valve replacement for aortic stenosis caused by alkaptonuria.

Authors:  Junko Hiroyoshi; Aya Saito; Nirmal Panthee; Yasushi Imai; Dai Kawashima; Noboru Motomura; Minoru Ono
Journal:  Ann Thorac Surg       Date:  2013-03       Impact factor: 4.330

3.  Evaluation of anti-oxidant treatments in an in vitro model of alkaptonuric ochronosis.

Authors:  Daniela Braconi; Marcella Laschi; Loredana Amato; Giulia Bernardini; Lia Millucci; Roberto Marcolongo; Giovanni Cavallo; Adriano Spreafico; Annalisa Santucci
Journal:  Rheumatology (Oxford)       Date:  2010-07-02       Impact factor: 7.580

4.  Development of an in vitro model to investigate joint ochronosis in alkaptonuria.

Authors:  Laura Tinti; Adam M Taylor; Annalisa Santucci; Brenda Wlodarski; Peter J Wilson; Jonathan C Jarvis; William D Fraser; John S Davidson; Lakshminarayan R Ranganath; James A Gallagher
Journal:  Rheumatology (Oxford)       Date:  2010-10-15       Impact factor: 7.580

5.  Proteomic and redox-proteomic evaluation of homogentisic acid and ascorbic acid effects on human articular chondrocytes.

Authors:  Daniela Braconi; Marcella Laschi; Adam M Taylor; Giulia Bernardini; Adriano Spreafico; Laura Tinti; James A Gallagher; Annalisa Santucci
Journal:  J Cell Biochem       Date:  2010-11-01       Impact factor: 4.429

6.  Choice of valve prosthesis in a rare clinical condition: aortic stenosis due to alkaptonuria.

Authors:  Sameer Thakur; Phuong Markman; Hugh Cullen
Journal:  Heart Lung Circ       Date:  2013-01-26       Impact factor: 2.975

Review 7.  Alkaptonuria-associated aortic stenosis.

Authors:  Zoe S Y Lok; Jacob Goldstein; Julian A Smith
Journal:  J Card Surg       Date:  2013-07       Impact factor: 1.620

8.  Redox-proteomics of the effects of homogentisic acid in an in vitro human serum model of alkaptonuric ochronosis.

Authors:  Daniela Braconi; Claretta Bianchini; Giulia Bernardini; Marcella Laschi; Lia Millucci; Adriano Spreafico; Annalisa Santucci
Journal:  J Inherit Metab Dis       Date:  2011-08-27       Impact factor: 4.982

9.  Biochemical and proteomic characterization of alkaptonuric chondrocytes.

Authors:  Daniela Braconi; Giulia Bernardini; Claretta Bianchini; Marcella Laschi; Lia Millucci; Loredana Amato; Laura Tinti; Tommaso Serchi; Federico Chellini; Adriano Spreafico; Annalisa Santucci
Journal:  J Cell Physiol       Date:  2012-09       Impact factor: 6.384

10.  Alkaptonuria is a novel human secondary amyloidogenic disease.

Authors:  Lia Millucci; Adriano Spreafico; Laura Tinti; Daniela Braconi; Lorenzo Ghezzi; Eugenio Paccagnini; Giulia Bernardini; Loredana Amato; Marcella Laschi; Enrico Selvi; Mauro Galeazzi; Alessandro Mannoni; Maurizio Benucci; Pietro Lupetti; Federico Chellini; Maurizio Orlandini; Annalisa Santucci
Journal:  Biochim Biophys Acta       Date:  2012-07-28
  10 in total
  7 in total

1.  Investigating the Robustness and Diagnostic Potential of Extracellular Matrix Remodelling Biomarkers in Alkaptonuria.

Authors:  F Genovese; A S Siebuhr; K Musa; J A Gallagher; A M Milan; M A Karsdal; J Rovensky; A C Bay-Jensen; L R Ranganath
Journal:  JIMD Rep       Date:  2015-03-19

Review 2.  Amyloidosis in alkaptonuria.

Authors:  Lia Millucci; Daniela Braconi; Giulia Bernardini; Pietro Lupetti; Josef Rovensky; Lakshminaryan Ranganath; Annalisa Santucci
Journal:  J Inherit Metab Dis       Date:  2015-04-14       Impact factor: 4.982

3.  Interactive alkaptonuria database: investigating clinical data to improve patient care in a rare disease.

Authors:  Vittoria Cicaloni; Ottavia Spiga; Giovanna Maria Dimitri; Rebecca Maiocchi; Lia Millucci; Daniela Giustarini; Giulia Bernardini; Andrea Bernini; Barbara Marzocchi; Daniela Braconi; Annalisa Santucci
Journal:  FASEB J       Date:  2019-08-28       Impact factor: 5.834

4.  Chondroptosis in alkaptonuric cartilage.

Authors:  Lia Millucci; Giovanna Giorgetti; Cecilia Viti; Lorenzo Ghezzi; Silvia Gambassi; Daniela Braconi; Barbara Marzocchi; Alessandro Paffetti; Pietro Lupetti; Giulia Bernardini; Maurizio Orlandini; Annalisa Santucci
Journal:  J Cell Physiol       Date:  2015-05       Impact factor: 6.384

5.  Machine learning application for development of a data-driven predictive model able to investigate quality of life scores in a rare disease.

Authors:  Ottavia Spiga; Vittoria Cicaloni; Cosimo Fiorini; Alfonso Trezza; Anna Visibelli; Lia Millucci; Giulia Bernardini; Andrea Bernini; Barbara Marzocchi; Daniela Braconi; Filippo Prischi; Annalisa Santucci
Journal:  Orphanet J Rare Dis       Date:  2020-02-12       Impact factor: 4.123

6.  Towards a Precision Medicine Approach Based on Machine Learning for Tailoring Medical Treatment in Alkaptonuria.

Authors:  Ottavia Spiga; Vittoria Cicaloni; Anna Visibelli; Alessandro Davoli; Maria Ausilia Paparo; Maurizio Orlandini; Barbara Vecchi; Annalisa Santucci
Journal:  Int J Mol Sci       Date:  2021-01-26       Impact factor: 5.923

7.  Homogentisate 1,2 dioxygenase is expressed in brain: implications in alkaptonuria.

Authors:  Giulia Bernardini; Marcella Laschi; Michela Geminiani; Daniela Braconi; Elisa Vannuccini; Pietro Lupetti; Fabrizio Manetti; Lia Millucci; Annalisa Santucci
Journal:  J Inherit Metab Dis       Date:  2015-03-12       Impact factor: 4.982

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.